Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

This is How Billionaire Bill Ackman’s Pershing Square Lost Nearly 26% In Q1

Highly-scrutinized activist investor Bill Ackman is no longer on the list of the top 20 best-performing hedge fund managers, after Pershing Square Capital Management L.P. posted a net-of-fees loss of 20.5% in 2015 (the list measures the amount of money that hedge fund managers have made for their investors since the inception of their funds). Thinks have not improved any in 2016, as Mr. Ackman’s activist hedge fund has lost an additional 25.6% during the first quarter of the year, as revealed by a performance report posted on the fund’s website on Friday. This disappointing performance was the collective result from long positions in 11 companies as well as one short position. Data compiled by Insider Monkey shows that Pershing Square’s eight holdings on December 31 in companies with a market capitalization of at least $1.0 billion generated a weighted average loss of 10.9% for the quarter, based on the size of those positions at the beginning of the first quarter. Obviously, much of the activist hedge fund’s losses can be attributed to battered drugmaker Valeant Pharmaceuticals Intl Inc. (NYSE:VRX), so let’s take a look at the performance of tha stock during the first quarter, as well as four other stocks owned by Pershing Square.

At Insider Monkey, we track around 785 hedge funds and institutional investors. Through extensive backtests, we have determined that imitating some of the stocks that these investors are collectively bullish on can help retail investors generate double digits of alpha per year. The key is to focus on the small-cap picks of these funds, which are usually less followed by the broader market and allow for larger price inefficiencies (see more details about our small-cap strategy).

Bill Ackman
Bill Ackman
Pershing Square

#5 Valeant Pharmaceuticals Intl Inc. (NYSE:VRX)

 – Shares Owned by Pershing Square (as of December 31): 16.59 Million

 – Value of Pershing Square’s Holding (as of December 31): $1.69 Billion

 – Q1 Return: -74.1%

Pershing Square owned a total of 16.59 million shares of Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) at the end of December, which were valued at $1.69 billion. Fresh 13D filings with the SEC show that Mr. Ackman’s fund now owns 30.71 million shares of the drug company, which constitute 9.0% of its total outstanding shares. This stake includes 21.59 million shares of common stock, a 5.00 million share increase to its long position, as well as an additional 9.12 million shares underlying over-the-counter American-style call options. Valeant’s shares have lost 85% in the past 12 months, after politicians attacked the drugmaker for gouging customers with unfounded price increases for its drugs and short-sellers condemned the company’s relationship with Philidor and pinpointed accounting irregularities associated with that relationship. The shares of the Canadian drugmaker have been under even more pressure this year after the company issued disappointing guidance for the current year, which raised the prospect that Valeant may default on its enormous debt should the company fail to file its Form 10-K and Form 10-Q. The recent appointment of Mr. Ackman to the company’s Board of Directors and the departure of Chief Executive Mike Pearson have done very little to restore investors’ confidence in the battered company. Jeffrey Ubben’s ValueAct Holdings L.P. owns 14.99 million shares of Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) as of the end of December.

Follow Valeant Pharmaceuticals International (NYSE:VRX)
Trade (NYSE:VRX) Now!

The following two pages discuss the performance of Mr. Ackman’s top four stock picks during the first quarter.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.